{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=AG-221&page=2", "query": { "intervention": "AG-221", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=AG-221&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-09-27T19:31:18.571Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03515512", "title": "IDH2 Inhibition Using Enasidenib as Maintenance Therapy for IDH2-mutant Myeloid Neoplasms Following Allogeneic Stem Cell Transplantation", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Acute Myeloid Leukemia", "Chronic Myelomonocytic Leukemia" ], "interventions": [ { "name": "Enasidenib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Massachusetts General Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 23, "start_date": "2018-07-17", "completion_date": "2023-02-13", "has_results": false, "last_update_posted_date": "2025-10-14", "last_synced_at": "2026-09-27T19:31:18.571Z", "location_count": 4, "location_summary": "Baltimore, Maryland • Boston, Massachusetts • Columbus, Ohio", "locations": [ { "city": "Baltimore", "state": "Maryland" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Columbus", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT03515512" }, { "nct_id": "NCT02665065", "title": "Study of Iomab-B vs. Conventional Care in Older Subjects With Active, Relapsed or Refractory Acute Myeloid Leukemia", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Acute Myeloid Leukemia", "Leukemia, Acute Myeloid", "Myeloid Leukemia, Acute", "Leukemia, Myeloid, Acute", "Acute Myelogenous Leukemia", "Leukemia, Acute Myelogenous", "Myelogenous Leukemia, Acute", "AML", "Bone Marrow Transplant" ], "interventions": [ { "name": "Iomab-B", "type": "DRUG" }, { "name": "Conventional Care", "type": "DRUG" }, { "name": "HCT", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "Actinium Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "55 Years", "maximum_age": null, "sex": "ALL", "summary": "55 Years and older" }, "enrollment_count": 153, "start_date": "2016-06", "completion_date": "2026-12", "has_results": false, "last_update_posted_date": "2023-07-19", "last_synced_at": "2026-09-27T19:31:18.571Z", "location_count": 22, "location_summary": "Gilbert, Arizona • New Haven, Connecticut • Washington D.C., District of Columbia + 18 more", "locations": [ { "city": "Gilbert", "state": "Arizona" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Maywood", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT02665065" }, { "nct_id": "NCT06176989", "title": "Enasidenib in IDH2-Mutated Malignant Sinonasal and Skull Base Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Chondrosarcoma", "Locally Advanced Chondrosarcoma", "Metastatic Sinonasal Adenocarcinoma", "Locally Advanced Sinonasal Adenocarcinoma", "Metastatic Large-cell Neuroendocrine Carcinoma", "Locally Advanced Large-cell Neuroendocrine Carcinoma", "Metastatic Olfactory Neuroblastoma", "Locally Advanced Olfactory Neuroblastoma", "Metastatic Sinonasal Undifferentiated Carcinoma", "Locally Advanced Sinonasal Undifferentiated Carcinoma" ], "interventions": [ { "name": "Enasidenib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "18 Years to 120 Years" }, "enrollment_count": 40, "start_date": "2024-03-04", "completion_date": "2030-12-31", "has_results": false, "last_update_posted_date": "2026-09-21", "last_synced_at": "2026-09-27T19:31:18.571Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT06176989" }, { "nct_id": "NCT03728335", "title": "Enasidenib (AG-221) Maintenance Post Allogeneic HCT in Patients With IDH2 Mutation", "overall_status": "SUSPENDED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Acute Myeloid Leukemia" ], "interventions": [ { "name": "Enasidenib Mesylate", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "City of Hope Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 35, "start_date": "2019-12-23", "completion_date": "2027-01-11", "has_results": false, "last_update_posted_date": "2026-08-21", "last_synced_at": "2026-09-27T19:31:18.571Z", "location_count": 2, "location_summary": "Duarte, California • Tampa, Florida", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT03728335" }, { "nct_id": "NCT02677922", "title": "A Study to Assess the Safety and Efficacy of Two Combinations of Isocitrate Dehydrogenase (IDH) Mutant Targeted Therapies Plus Azacitidine in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) Harboring IDH Mutations Who Are Not Candidates to Receive Intensive Induction Chemotherapy", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Leukemia, Myeloid, Acute" ], "interventions": [ { "name": "AG-120", "type": "DRUG" }, { "name": "Azacitidine", "type": "DRUG" }, { "name": "AG-221", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Celgene", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 130, "start_date": "2016-06-03", "completion_date": "2026-09-30", "has_results": true, "last_update_posted_date": "2026-02-19", "last_synced_at": "2026-09-27T19:31:18.571Z", "location_count": 9, "location_summary": "Duarte, California • New Haven, Connecticut • Chicago, Illinois + 3 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT02677922" }, { "nct_id": "NCT05010772", "title": "Decitabine Alone or in Combination With Venetoclax, Gilteritinib, Enasidenib, or Ivosidenib as Maintenance Therapy for the Treatment of Acute Myeloid Leukemia in Remission", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Acute Myeloid Leukemia" ], "interventions": [ { "name": "Decitabine and Cedazuridine", "type": "DRUG" }, { "name": "Enasidenib", "type": "DRUG" }, { "name": "Gilteritinib", "type": "DRUG" }, { "name": "Ivosidenib", "type": "DRUG" }, { "name": "Venetoclax", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 125, "start_date": "2021-10-25", "completion_date": "2026-12-31", "has_results": false, "last_update_posted_date": "2026-07-16", "last_synced_at": "2026-09-27T19:31:18.571Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT05010772" }, { "nct_id": "NCT04573582", "title": "Pharmacokinetics of Enasidenib (CC-90007) in Participants With Mild, Moderate and Severe Hepatic Impairment", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Hepatic Impairment" ], "interventions": [ { "name": "Enasidenib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Celgene", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "40 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "40 Years to 75 Years" }, "enrollment_count": 40, "start_date": "2020-11-13", "completion_date": "2023-03-08", "has_results": false, "last_update_posted_date": "2024-07-15", "last_synced_at": "2026-09-27T19:31:18.571Z", "location_count": 3, "location_summary": "Miami, Florida • Orlando, Florida • Knoxville, Tennessee", "locations": [ { "city": "Miami", "state": "Florida" }, { "city": "Orlando", "state": "Florida" }, { "city": "Knoxville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT04573582" }, { "nct_id": "NCT03825796", "title": "CPX-351 Plus Enasidenib for Relapsed AML", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Recurrent Acute Myeloid Leukemia" ], "interventions": [ { "name": "Enasidenib Mesylate", "type": "DRUG" }, { "name": "Liposome-encapsulated Daunorubicin-Cytarabine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Jonsson Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 2, "start_date": "2019-04-12", "completion_date": "2024-09-01", "has_results": false, "last_update_posted_date": "2023-09-28", "last_synced_at": "2026-09-27T19:31:18.571Z", "location_count": 3, "location_summary": "Los Angeles, California • Sacramento, California • San Diego, California", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "San Diego", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03825796" }, { "nct_id": "NCT03732703", "title": "Myeloma-Developing Regimens Using Genomics (MyDRUG)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Relapsed Refractory Multiple Myeloma" ], "interventions": [ { "name": "Abemaciclib, dexamethasone, ixazomib, pomalidomide", "type": "DRUG" }, { "name": "Enasidenib, dexamethasone, ixazomib, pomalidomide", "type": "DRUG" }, { "name": "Cobimetinib, dexamethasone, ixazomib, pomalidomide", "type": "DRUG" }, { "name": "Erdafitinib, dexamethasone, ixazomib, pomalidomide", "type": "DRUG" }, { "name": "Venetoclax, dexamethasone, ixazomib, pomalidomide", "type": "DRUG" }, { "name": "Daratumumab, dexamethasone, ixazomib, pomalidomide", "type": "DRUG" }, { "name": "Belantamab mafodotin, dexamethasone, ixazomib, pomalidomide", "type": "DRUG" }, { "name": "Selinexor, dexamethasone, ixazomib, pomalidomide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Multiple Myeloma Research Consortium", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 103, "start_date": "2019-04-01", "completion_date": "2024-12-31", "has_results": false, "last_update_posted_date": "2025-02-14", "last_synced_at": "2026-09-27T19:31:18.571Z", "location_count": 16, "location_summary": "Phoenix, Arizona • Duarte, California • Atlanta, Georgia + 10 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Duarte", "state": "California" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT03732703" }, { "nct_id": "NCT05282459", "title": "Enasidenib in MDS &Non-proliferative Chronic Myelomonocytic Leukemia w/o IDH2 Mutation", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Leukemia", "Leukemia, Myeloid", "Monocytic Leukemia" ], "interventions": [ { "name": "Enasidenib mesylat dose escalation", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Tian Yi Zhang", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 17, "start_date": "2022-01-12", "completion_date": "2025-03-03", "has_results": true, "last_update_posted_date": "2026-09-03", "last_synced_at": "2026-09-27T19:31:18.571Z", "location_count": 1, "location_summary": "Palo Alto, California", "locations": [ { "city": "Palo Alto", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05282459" } ] }